The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
|
|---|---|
| Published in |
Frontiers in immunology, January 2018
|
| DOI | 10.3389/fimmu.2017.01911 |
| Pubmed ID | |
| Authors |
Kristina M. Ilieva, Anthony Cheung, Silvia Mele, Giulia Chiaruttini, Silvia Crescioli, Merope Griffin, Mano Nakamura, James F. Spicer, Sophia Tsoka, Katie E. Lacy, Andrew N. J. Tutt, Sophia N. Karagiannis |
| Abstract |
Overexpression of the chondroitin sulfate proteoglycan 4 (CSPG4) has been associated with the pathology of multiple types of such as melanoma, breast cancer, squamous cell carcinoma, mesothelioma, neuroblastoma, adult and pediatric sarcomas, and some hematological cancers. CSPG4 has been reported to exhibit a role in the growth and survival as well as in the spreading and metastasis of tumor cells. CSPG4 is overexpressed in several malignant diseases, while it is thought to have restricted and low expression in normal tissues. Thus, CSPG4 has become the target of numerous anticancer treatment approaches, including monoclonal antibody-based therapies. This study reviews key potential anti-CSPG4 antibody and immune-based therapies and examines their direct antiproliferative/metastatic and immune activating mechanisms of action. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 157 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 157 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 17% |
| Student > Master | 15 | 10% |
| Student > Bachelor | 14 | 9% |
| Researcher | 13 | 8% |
| Other | 8 | 5% |
| Other | 21 | 13% |
| Unknown | 59 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 28 | 18% |
| Medicine and Dentistry | 17 | 11% |
| Immunology and Microbiology | 15 | 10% |
| Agricultural and Biological Sciences | 14 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 17 | 11% |
| Unknown | 62 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2018.
All research outputs
#15,609,489
of 26,161,782 outputs
Outputs from Frontiers in immunology
#14,419
of 33,001 outputs
Outputs of similar age
#240,228
of 456,638 outputs
Outputs of similar age from Frontiers in immunology
#350
of 615 outputs
Altmetric has tracked 26,161,782 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 33,001 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 456,638 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 615 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.